The Global Antibiotic R&D Partnership(GARDP) will host a live webinar with ApconiX’s Dr Claire Sadler on ”Making safety a part of drug design” on 13th November 16.00-17.30 GMT.
Claire is an expert discovery project toxicologist specialising in early project safety assessment and risk mitigation. In this webinar, she discusses the toxicological challenges and pitfalls of antibiotic discovery programmes. Potential safety risks are the major reason for terminating a programme in early phases of antibiotic drug development. This webinar will help identifying the most common toxicology risks associated with antibiotic discovery and discuss potential mitigating strategies.
Moderated by Ursula Theuretzbacher, this presentation was part of the recent GARDP and CARB-X co-organized session ‘Antibiotic Bootcamps for Developers: Preclinical Toxicology’ held at the ESCMID/ASM Conference on Drug Development.
Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath. A co-founder of ApconiX, Ruth has 25 years of experience in leading roles in drug safety within large pharma. Ruth is also Chair and Director of Drug Discovery at The University of Birmingham, UK and was previously Global Head of Regulatory Safety at AstraZeneca. With over 140 publications in peer-reviewed journals, she is former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and President of the Academy of Toxicological Sciences. Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development.